The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase III randomized trial of eribulin (E) with or without gemcitabine versus standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937.
 
Sarmad Sadeghi
Consulting or Advisory Role - Cardiff Oncology (I); Cardinal Health
Research Funding - Merck; Pfizer
 
Melissa Plets
No Relationships to Disclose
 
Primo "Lucky" N. Lara
Consulting or Advisory Role - Calithera Biosciences (Inst); Janssen
Research Funding - Janssen Biotech (Inst); Taiho Pharmaceutical (Inst)
 
Catherine Tangen
No Relationships to Disclose
 
Rick Bangs
Other Relationship - ASCO; Bladder Cancer Advocacy Network; Facing our Risk of Cancer Empowered; Facing our Risk of Cancer Empowered; Institute for Clinical and Economic Review; National Cancer Institute; National Cancer Institute; National Cancer Institute; National Cancer Institute; National Cancer Institute; National Comprehensive Cancer Network; SWOG; SWOG; SWOG; University of Puerto Rico
 
Seth P. Lerner
Stock and Other Ownership Interests - C2i genomics
Honoraria - Annenberg Center for Health Sciences at Eisenhower (ACHS); Clinical Care Options; Grand Rounds in Urology; Ology Medical Education; UroToday
Consulting or Advisory Role - AstraZeneca; Aura Biosciences; C2i Genomics; FerGene; Ferring; Merck Sharp & Dohme; Pfizer/EMD Serono; Roche/Genentech; Urogen pharma; Vaxiion; Verity Pharmaceuticals
Research Funding - Endo Pharmaceuticals; FKD Therapies; Japan BCG Laboratory; QED Therapeutics; Roche/Genentech; Urogen pharma; Vaxiion; Viventia Biotech
Patents, Royalties, Other Intellectual Property - TCGA expression subtype singel patient classifier
Other Relationship - Bladder Cancer Journal; UpToDate
 
Thomas W. Flaig
Leadership - Aurora Oncology
Stock and Other Ownership Interests - Aurora Oncology
Consulting or Advisory Role - Janssen Oncology; Seagen
Research Funding - Agensys; Aragon Pharmaceuticals; Astellas Pharma; astrazeneca/MedImmune; Bavarian Nordic; Bristol-Myers Squibb; Dendreon; Exelixis; GTx; Janssen Oncology; La Roche-Posay; Lilly; Medivation; Merck; Novartis; Pfizer; Roche/Genentech; Sanofi; Seagen; Seagen; Sotio; Tokai Pharmaceuticals
Patents, Royalties, Other Intellectual Property - The University of Colorado has filed 2 patents related in which I am an inventor. These are related to early-stage bladder cancer treatment and detection. Neither is commercialized or licensed at this time.
 
Daniel P. Petrylak
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; TYME
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bicycle Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Gilead Sciences; Incyte; Ipsen; Janssen; Lilly; Mirati Therapeutics; Monopteros Therapeutics; Pfizer; Pharmacyclics; Regeneron; Roche; Seagen; Urogen pharma
Research Funding - Advanced Accelerator Applications (Inst); Agensys (Inst); Astellas Medivation (Inst); AstraZeneca (Inst); Bayer (Inst); BioXCel therapeutics (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); Endocyte (Inst); Genentech (Inst); Gilead Sciences (Inst); Innocrin Pharma (Inst); Lilly (Inst); MedImmune (Inst); Medivation (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Progenics (Inst); Replimune (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst)
Expert Testimony - Celgene; sanofi
 
Ian Thompson
Consulting or Advisory Role - Magforce; Profound Medical
Research Funding - MagForce
Patents, Royalties, Other Intellectual Property - I have several patents with colleagues involving novel biomarkers for cancer and two devices for sexual dysfunction and urinary incontinence. No revenues at this time and our University IP office is working with industry to determine if these can be comme